EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans

Tae-Bin Won, Hyung Gu Kim, Jeong-Whun Kim, Jin Kook Kim, Young Hyo Kim, Soo Whan Kim, Hyo Yeol Kim, Dae Woo Kim, Sung Wan Kim, Chang-Hoon Kim, Chae-Seo Rhee

Asian Pacific Journal of Allergy and Immunology · 2025

DOI: 10.12932/ap-201220-1019 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2025. Verfasst von Tae-Bin Won und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Cyproheptadine, Rhinitis, Allergic, Perennial. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The efficacy of rupatadine for the treatment of AR has been confirmed in numerous clinical studies, however there are very few studies on asian patients. OBJECTIVE: To assess the safety and efficacy of rupatadine fumarate in the treatment of Korean perennial allergic rhinitis (PAR) patients. METHODS: A multicenter, double-blind, randomized, placebo-controlled, comparative study of rupatadine fumarate and bepotastine besilate was conducted. Each group was administered rupatadine, bepotastine or placebo for 4 weeks. Primary parameters for efficacy included morning and evening symptom reduction from baseline at 4 weeks. Treatment safety and tolerability were evaluated according to a self-reported incidence and type of adverse events at each follow up visit. RESULTS: Rupatadine showed a significant reduction in symptoms at morning and evening evaluations, in both 5TSS (-5.69, P < 0.0006) and 4NTSS (-4.74, P < 0.0015) compared to placebo. There was a significant reduction from baseline for 5TSS (-65.4%, P = 0.002) and 4NTSS (-63.7%, P = 0.003) with rupatadine compared with placebo. At evening evaluations, there were significant reductions of 5TSS (-63.2%, P = 0.009) and 4NTSS (-61.6%, P = 0.013) for the rupatadine group. Compared with bepotastine, rupatadine showed greater reduction in the morning symptoms at 4 weeks. When individual symptoms were assessed with 12-hour reflective mean daily symptom score, rupatadine showed better efficacy than placebo in sneezing (P = 0.016) and rhinorrhea (P = 0.097). The rate of adverse events showed no statistical significance. CONCLUSIONS: Rupatadine is a safe and effective treatment option for Korean PAR patients and possibly a better choice over bepotastine for controlling morning symptom.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyproheptadineRhinitis, Allergic, PerennialHumansMaleFemaleAdultDouble-Blind MethodTreatment OutcomeMiddle AgedRepublic of KoreaYoung AdultAdolescentAnti-Allergic AgentsEast Asian People

Substanzen

rupatadineCyproheptadineAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Hospital, Seoul, Korea.
  • Department of Otorhinolaryngology-Head & Neck Surgery, Hanyang University Guri Hospital, Guri, Korea.
  • Department of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Konkuk University, Seoul, Korea.
  • Department of Otorhinolaryngology, Inha University, Incheon, Korea.
  • Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Zitieren

APA

Won, T. B., Kim, H. G., Kim, J. W., Kim, J. K., Kim, Y. H., Kim, S. W., Kim, H. Y., Kim, D. W., Kim, S. W., Kim, C. H., & Rhee, C. S. (2025). Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-201220-1019

Vancouver

Won TB, Kim HG, Kim JW, Kim JK, Kim YH, Kim SW, et al. Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans. Asian Pacific Journal of Allergy and Immunology. 2025. doi:10.12932/ap-201220-1019

BibTeX
@article{Won2025,
  author = {Won, Tae-Bin and Kim, Hyung Gu and Kim, Jeong-Whun and Kim, Jin Kook and Kim, Young Hyo and Kim, Soo Whan and Kim, Hyo Yeol and Kim, Dae Woo and Kim, Sung Wan and Kim, Chang-Hoon and Rhee, Chae-Seo},
  title = {Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans},
  journal = {Asian Pacific Journal of Allergy and Immunology},
  year = {2025},
  doi = {10.12932/ap-201220-1019}
}
Kostenlos starten →